Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Qinghua Zhixie is a Traditional Chinese Medicine (TCM) herbal formula developed by the Changshu Hospital of Traditional Chinese Medicine for the treatment of diarrhea-predominant irritable bowel syndrome (IBS-D). It is specifically indicated for patients presenting with the TCM patterns of Spleen Deficiency and Damp-Heat. The formula is designed to clear heat, resolve dampness, and tonify the spleen to alleviate gastrointestinal symptoms such as abdominal pain and frequent diarrhea. Clinical research, including randomized controlled trials, has focused on its ability to improve clinical symptom scores and its potential molecular mechanisms involving the regulation of gut microbiota and the intestinal mucosal barrier.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Qinghua Zhixie.